Mebutamate
Dormate (mebutamate) is a small molecule pharmaceutical. Mebutamate was first approved as Dormate on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mebutamate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DORMATE | Medpointe Pharm Hlc | N-017374 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Narcolepsy | D009290 | EFO_0000614 | G47.4 | — | 2 | — | — | — | 2 |
Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
Cocaine-related disorders | D019970 | F14 | — | 1 | — | — | — | 1 | |
Disorders of excessive somnolence | D006970 | G47.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | MEBUTAMATE |
INN | mebutamate |
Description | Mebutamate (Capla, Dormate) is an anxiolytic and sedative drug with antihypertensive effects of the carbamate class. It has effects comparable to those of barbiturates such as secobarbital, but is only around 1/3 the potency of secobarbital as a sedative. Side effects include dizziness and headaches.
|
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCC(C)C(C)(COC(N)=O)COC(N)=O |
Identifiers
PDB | — |
CAS-ID | 64-55-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1200922 |
ChEBI ID | — |
PubChem CID | 6151 |
DrugBank | DB06797 |
UNII ID | 5H8F175RER (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 40 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
33 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more